Related Experiment Video
Updated: Aug 16, 2026
CD4+ T-Lymphocyte Capture Using a Disposable Microfluidic Chip for HIV
Published on: October 1, 2007
Anti-CD 40 monoclonal antibody
1Cancer Research UK Oncology Unit, Cancer Sciences Division, School of Medicine, Southampton General Hospital, Southampton SO16 6YD, UK.
Insights
Monoclonal antibodies targeting CD 40 are a promising cancer therapy. These antibodies harness immune responses and directly attack cancer cells, showing potential in early clinical trials for various malignancies.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- CD 40 and CD 154 interactions are crucial for adaptive immunity.
- CD 40 is expressed on various hematological and epithelial cancers.
- Targeting CD 40 offers a novel therapeutic strategy in oncology.
Purpose of the Study:
- To review the role of CD 40 in immune responses.
- To explore the therapeutic potential of anti-CD 40 monoclonal antibodies.
- To summarize early clinical trial data for CD 40-targeted therapies.
Main Methods:
- Review of existing literature on CD 40 biology and function.
- Analysis of mechanisms of action for anti-CD 40 antibodies.
- Compilation and summary of early-phase clinical trial results.
Main Results:
- Anti-CD 40 antibodies engage multiple anti-cancer mechanisms.
- These mechanisms include complement-dependent and antibody-dependent cellular cytotoxicity.
- Early clinical data suggest potential efficacy in treating malignancies.
Conclusions:
- Targeting CD 40 with monoclonal antibodies is a promising therapeutic avenue.
- Further clinical investigation is warranted to establish the efficacy and safety of these agents.
- CD 40-targeted therapies represent a potentially exciting new treatment approach for cancer.
Abstract:
Normal, bi-directional interactions between CD 40 and its natural ligand CD 154 (CD 40 ligand) are central to the generation of both T cell-dependent, humoral immune responses and cytotoxic T-cell responses. CD 40 is expressed on a broad range of hematological and epithelial malignancies. The development of monoclonal antibodies directed against CD 40 allows effective targeting of malignant cells through multiple mechanisms that include the recruitment of immune effector mechanisms such as complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, direct anti-proliferative effects on neoplastic cells and, importantly, by the activation of tumor-targeted cellular cytotoxicity. This review provides the background to the early clinical trial data that are now beginning to emerge for this potentially exciting new treatment approach.
More Related Videos
07:10Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
Published on: September 14, 2014
10:44A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants
Published on: August 9, 2019
